Zacks: Brokerages Anticipate Alexion Pharmaceuticals, Inc. (ALXN) Will Announce Earnings of $1.28 Per Share
Wall Street analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post earnings per share of $1.28 for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Alexion Pharmaceuticals’ earnings. The highest EPS estimate is $1.53 and the lowest is $1.11. Alexion Pharmaceuticals posted earnings per share of $1.26 in the same quarter last year, which indicates a positive year over year growth rate of 1.6%. The company is scheduled to report its next quarterly earnings report on Thursday, February 15th.
On average, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $5.66 per share for the current fiscal year, with EPS estimates ranging from $5.50 to $5.90. For the next financial year, analysts expect that the firm will report earnings of $7.09 per share, with EPS estimates ranging from $6.50 to $8.64. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same period in the previous year, the firm posted $1.23 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis.
Several brokerages have commented on ALXN. Leerink Swann reissued a “buy” rating and set a $182.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective on the stock. Finally, BMO Capital Markets restated an “outperform” rating and set a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $154.01.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/22/zacks-brokerages-anticipate-alexion-pharmaceuticals-inc-alxn-will-announce-earnings-of-1-28-per-share.html.
In other news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,490 shares of company stock valued at $2,337,251. 4.35% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. Fiduciary Trust Co. bought a new position in Alexion Pharmaceuticals in the 2nd quarter valued at approximately $111,000. Valeo Financial Advisors LLC bought a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $147,000. Huntington National Bank lifted its stake in Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the last quarter. Dupont Capital Management Corp bought a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $156,000. Finally, BT Investment Management Ltd bought a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $165,000. 95.80% of the stock is owned by institutional investors and hedge funds.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $0.45 during trading hours on Wednesday, reaching $107.60. 1,800,615 shares of the company’s stock traded hands, compared to its average volume of 2,294,205. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a market cap of $24,040.00, a PE ratio of 22.19, a PEG ratio of 1.18 and a beta of 1.22.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.